Keywords: SK biopharma, Medicilon, SKL-PSY, Depression, Bipolar disease, Licensing

SK biopharma in licensing deal with China’s Medicilon for depression/bipolar drug candidate

Article | 02 November 2011

Print This

South Korean biotech firm SK biopharmaceuticals says it has entered into an R&D agreement with Medicilon, a drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in